Research and Markets has announced the addition of the "Ventricular
Arrhythmia - Global API Manufacturers, Marketed and Phase III Drugs
Landscape, 2017" drug pipelines to their offering.
Ventricular Arrhythmia - Global API Manufacturers, Marketed and Phase
III Drugs Landscape, 2017, provides comprehensive insights about the
marketed drugs, drug sales, Phase III pipeline drugs and their API
Manufacturers across the globe.
A key objective of the Ventricular Arrhythmia Report is to understand
the market and pipeline status of the drugs around the Ventricular
Arrhythmia to explore the generic development opportunities, licensing
opportunities and to gain competitive advantage on designing pipeline
strategies. The Report provides the historical and forecasted sales of
the drugs till 2018.
The Ventricular Arrhythmia Report gives insights into patents providing
the patent protection data and marketing exclusivity of all the drugs
across the Ventricular Arrhythmia.
While the leading brands, companies and chemicals are considered
thoroughly, the report also provides details on the Global API
Manufacturers across the globe covering Drug Master Filings of US,
Europe and API Manufacturers in Asia specifically China and India.
Key Topics Covered:
1. Indication Overview
2. Market Drugs Landscape
3. Global API Manufacturers Assessment
4. Phase III Drugs Landscape
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Ventricular Arrhythmia
7. Phase III Drugs for Ventricular Arrhythmia
8. Discontinued Drugs for Ventricular Arrhythmia
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/cs9gkq/ventricular
View source version on businesswire.com: http://www.businesswire.com/news/home/20170217005664/en/